THERAPEUTIC CUT-OFF OF INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

被引：0
|
作者：
Nagore, D. [1 ]
Ruiz del Agua, A. [1 ]
Pascual, J. [1 ]
Llinares-Tello, F. [2 ]
Herreros, B. [3 ]
Martinez, A. [1 ]
Martin, S. [1 ,4 ]
Navarro, R. [5 ]
机构：
[1] Progenika, R&D, Derio, Spain
[2] Hosp Marina Baixa, Clin Anal, Villajoyosa, Spain
[3] Hosp Marina Baixa, Digest Dis, Villajoyosa, Spain
[4] Univ Basque Country UPV EHU, Sch Med & Dent, Zabalduz Scholarship Programme, Dept Physiol, Leioa, Spain
[5] Univ Basque Country UPV EHU, Sch Med & Dent, Dept Physiol, Leioa, Spain
来源：
GUT | 2015年 / 64卷
关键词：
D O I：
10.1136/gutjnl-2015-309861.202
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PTU-087
引用
收藏
页码：A99 / A99
页数：1
相关论文
共 50 条
  • [21] INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    Caprioli, F.
    Bose, F.
    Raeli, L.
    Vigano, C.
    Basilisco, G.
    Conte, D.
    Abrignani, S.
    Reali, E.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S125 - S125
  • [22] CUT-OFF
    MORAN, R
    COMPUTER DECISIONS, 1988, 20 (08): : 65 - 69
  • [23] IDENTIFICATION OF A CUT-OFF FOR PERSISTENT ANTI-INFLIXIMAB ANTIBODIES AS A PREDICTOR OF RESPONSE TO INFLIXIMAB MONOTHERAPY
    Del Nero, L.
    Bodini, G.
    Giannini, E. G.
    Savarino, V
    De Maria, C.
    Baldissarro, I
    Savarino, E.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E77 - E77
  • [24] Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
    Kolar, M.
    Duricova, D.
    Bortlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M., Jr.
    Lukas, Milan
    DIGESTIVE DISEASES, 2017, 35 (1-2) : 91 - 100
  • [25] Identification of a cut-off for persistent anti-infliximab antibodies as a predictor of response to infliximab monotherapy
    Del Nero, L.
    Bodini, G.
    Giannini, E.
    Anjali, J.
    Savarino, V.
    Savarino, E.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S270 - S271
  • [26] HIGH CUT-OFF HAEMODIALYSIS LOWERS INFLAMMATORY STATUS IN CHRONIC DIALYSIS PATIENTS
    Hutchison, C. A.
    Meryon, I.
    Edwards, N.
    Hewins, P.
    Whitelegg, A.
    Drayson, M.
    Cockwell, P.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (07): : 592 - 593
  • [27] SERUM INFLIXIMAB LEVELS,ANTIBODIES TO INFLIXIMAB AND ALBUMIN CONCENTRATIONS DURING INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    Malickova, K.
    Janatkova, I.
    Duricova, D.
    Bortlik, M.
    Lukas, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 213 - 213
  • [28] A Study on the Optimal Cut-off Point in the Cut-off Sampling Method
    Lee, Sang Eun
    Cho, Min Ji
    Shin, Key-Il
    KOREAN JOURNAL OF APPLIED STATISTICS, 2014, 27 (03) : 501 - 512
  • [29] The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases
    Bothorel, L.
    Laharie, D.
    Poullenot, F.
    Gohier, E.
    Chevrier, C.
    Berger, A.
    Zerbib, F.
    Riviere, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1490 - I1490
  • [30] ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases
    Jung, Eun Suk
    Choi, Ko-Woon
    Kim, Seung Won
    Huebenthal, Matthias
    Mucha, Soeren
    Park, Jihye
    Park, Zewon
    Ellinghaus, David
    Schreiber, Stefan
    Franke, Andre
    Oh, Woo Yong
    Cheon, Jae Hee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (10) : 1727 - 1735
12345